GILD analyst scorecard · Gilead Sciences
48 rating actions on GILD in the last 12 months. Of 75 price targets that resolved, 28 were reached while they stood, 46 were replaced by the same firm first, and 1 fell short at their deadline. Ratings: 81% Buy-type, 19% Hold-type, 0% Sell-type. Consensus target $160, 1% below the last close.
Checked through 2026-10-29 · last close $162.37 (2026-10-29). Rebuilt every morning.
What the Holds say: 9 Hold-type ratings on GILD in the last 12 months carried a median target -7% from the price on the day; 78% sat below it.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Overweight | 2026-10-08 | $155 | 5 | 2 | 7 | — |
| Morgan Stanley | Overweight | 2026-10-07 | $163 | 1 | 8 | 9 | 1 of 1 |
| Truist Securities | Buy | 2026-10-07 | $158 | 2 | 3 | 5 | 0 of 1 |
| Needham | Buy | 2026-08-05 | $170 | 1 | 2 | 3 | 0 of 1 |
| JPMorgan | Overweight | 2026-10-07 | $170 | 1 | 5 | 6 | 1 of 1 |
| HSBC | Buy | 2026-09-10 | $175 | 0 | 1 | 1 | — |
| UBS | Buy | 2026-01-26 | $155 | 3 | 0 | 3 | — |
| RBC Capital | Sector Perform | 2026-10-08 | $126 | 1 | 11 | 12 | — |
| Citigroup | Buy | 2026-04-13 | $165 | 1 | 3 | 4 | 1 of 1 |
| Wells Fargo | Overweight | 2026-02-11 | $165 | 1 | 4 | 5 | 1 of 1 |
| Barclays | Equal-Weight | 2026-07-29 | $145 | 1 | 0 | 1 | — |
| Scotiabank | Sector Outperform | 2026-02-11 | $177 | 1 | 0 | 1 | — |
| Bank of America | Buy | 2026-10-20 | $172 | 1 | 1 | 2 | 1 of 1 |
| Leerink Partners | Market Perform | 2026-07-21 | $127 | — | — | 0 | — |
| Maxim Group | Buy | 2026-05-20 | $165 | — | — | 0 | — |
| Jefferies | Buy | 2026-03-10 | $180 | — | — | 0 | — |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor GILD carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Bank of America | Buy | maintained | $156.51 | $172 | running to 2027-10-20 | +4.3% |
| 2026-10-08 | RBC Capital | Sector Perform | maintained | $147.10 | $126 | running to 2027-10-08 | +0.3% |
| 2026-10-08 | Cantor Fitzgerald | Overweight | reiterated | $147.10 | $155 | reached 2026-10-15 | +0.3% |
| 2026-10-07 | Truist Securities | Buy | maintained | $146.85 | $158 | reached 2026-10-26 | -2.8% |
| 2026-10-07 | JPMorgan | Overweight | maintained | $146.85 | $170 | running to 2027-10-07 | -2.8% |
| 2026-10-07 | Morgan Stanley | Overweight | maintained | $146.85 | $163 | running to 2028-04-07 | -2.8% |
| 2026-09-10 | HSBC | Buy | maintained | $144.81 | $175 | running to 2027-09-10 | +6.7% |
| 2026-08-05 | RBC Capital | Sector Perform | maintained | $131.76 | $123 | replaced 2026-10-08, new $126 | +1.7% |
| 2026-08-05 | Cantor Fitzgerald | Overweight | reiterated | $131.76 | $155 | reached 2026-10-15 | +1.7% |
| 2026-08-05 | Needham | Buy | reiterated | $131.76 | $170 | running to 2027-08-05 | +1.7% |
| 2026-07-29 | Barclays | Equal-Weight | maintained | $132.73 | $145 | reached 2026-08-19 | +5.1% |
| 2026-07-27 | Morgan Stanley | Overweight | maintained | $130.52 | $165 | replaced 2026-10-07, new $163 | +2.1% |
| 2026-07-21 | Leerink Partners | Outperform → Market Perform | downgrade | $130.28 | $127 | within 5% of price when set | +5.3% |
| 2026-07-08 | Morgan Stanley | Overweight | maintained | $135.82 | $166 | replaced 2026-07-27, new $165 | +6.0% |
| 2026-07-07 | RBC Capital | Sector Perform | maintained | $136.36 | $120 | replaced 2026-08-05, new $123 | +5.6% |
| 2026-07-07 | Truist Securities | Buy | maintained | $136.36 | $156 | replaced 2026-10-07, new $158 | +5.6% |
| 2026-07-06 | Cantor Fitzgerald | Overweight | reiterated | $129.61 | $155 | reached 2026-10-15 | +0.3% |
| 2026-07-06 | HSBC | Hold → Buy | upgrade | $129.61 | $155 | replaced 2026-09-10, new $175 | +0.3% |
| 2026-06-16 | Cantor Fitzgerald | Overweight | reiterated | $127.23 | $155 | reached 2026-10-15 | -1.8% |
| 2026-05-20 | Maxim Group | Hold → Buy | upgrade | $130.69 | $165 | running to 2027-05-20 | -3.8% |
| 2026-05-08 | Truist Securities | Buy | reiterated | $131.33 | $157 | replaced 2026-07-07, new $156 | -7.2% |
| 2026-05-08 | RBC Capital | Sector Perform | maintained | $131.33 | $122 | reached 2026-06-10 | -7.2% |
| 2026-04-13 | Citigroup | Buy | maintained | $139.03 | $165 | running to 2027-04-13 | -4.1% |
| 2026-04-10 | Morgan Stanley | Overweight | maintained | $138.99 | $175 | replaced 2026-07-08, new $166 | -4.8% |
| 2026-03-10 | Jefferies | Buy | initiated | $148.56 | $180 | running to 2027-03-10 | -2.6% |
| 2026-02-23 | Needham | Buy | reiterated | $149.83 | $170 | running to 2027-02-23 | +10.2% |
| 2026-02-20 | Barclays | Equal-Weight | initiated | $151.40 | $155 | within 5% of price when set | +17.3% |
| 2026-02-11 | RBC Capital | Sector Perform | maintained | $155.80 | $118 | replaced 2026-05-08, new $122 | +27.1% |
| 2026-02-11 | Truist Securities | Buy | maintained | $155.80 | $152 | within 5% of price when set | +27.1% |
| 2026-02-11 | Wells Fargo | Overweight | maintained | $155.80 | $165 | running to 2027-02-11 | +27.1% |
| 2026-02-11 | Cantor Fitzgerald | Overweight | maintained | $155.80 | $155 | within 5% of price when set | +27.1% |
| 2026-02-11 | Scotiabank | Sector Outperform | maintained | $155.80 | $177 | running to 2027-02-11 | +27.1% |
| 2026-02-11 | Needham | Buy | maintained | $155.80 | $170 | running to 2027-02-11 | +27.1% |
| 2026-01-27 | Truist Securities | Buy | maintained | $140.97 | $145 | within 5% of price when set | +13.1% |
| 2026-01-27 | Citigroup | Buy | maintained | $140.97 | $156 | replaced 2026-04-13, new $165 | +13.1% |
| 2026-01-26 | UBS | Buy | maintained | $137.78 | $155 | reached 2026-02-11 | +10.5% |
| 2026-01-13 | Morgan Stanley | Overweight | maintained | $121.76 | $150 | reached 2026-02-06 | +1.1% |
| 2026-01-07 | Citigroup | Buy | maintained | $124.35 | $140 | reached 2026-01-27 | +2.6% |
| 2025-12-12 | Morgan Stanley | Overweight | maintained | $120.40 | $151 | replaced 2026-01-13, new $150 | -2.4% |
| 2025-12-10 | Wells Fargo | Overweight | maintained | $121.34 | $150 | reached 2026-02-06 | +2.7% |
| 2025-11-13 | Needham | Buy | maintained | $125.20 | $140 | reached 2026-01-27 | — |
| 2025-11-13 | Scotiabank | Sector Outperform | initiated | $125.20 | $140 | reached 2026-01-27 | — |
| 2025-11-03 | Truist Securities | Buy | reiterated | $122.05 | $145 | reached 2026-02-04 | — |
| 2025-10-31 | Wells Fargo | Overweight | maintained | $119.79 | $145 | replaced 2025-12-10, new $150 | — |
| 2025-10-31 | JPMorgan | Overweight | maintained | $119.79 | $150 | reached 2026-02-06 | — |
| 2025-10-31 | RBC Capital | Sector Perform | maintained | $119.79 | $105 | replaced 2026-02-11, new $118 | — |
| 2025-10-31 | Cantor Fitzgerald | Overweight | reiterated | $119.79 | $135 | reached 2026-01-23 | — |
| 2025-10-31 | Needham | Buy | reiterated | $119.79 | $133 | replaced 2025-11-13, new $140 | — |
Also in Biotech
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.